Kanold J, Paillard C, Tchirkov A, Merlin E, Marabelle A, Lutz P, Rousseau R, Baldomero H, Deméocq F
Centre Hospitalier et Universitaire de Clermont-Ferrand, Service de Pédiatrie B et Unité Bioclinique de Thérapie Cellulaire, Clermont-Ferrand, France.
Bone Marrow Transplant. 2008 Oct;42 Suppl 2:S25-30. doi: 10.1038/bmt.2008.279.
New concepts of allogeneic hematopoietic SCT (allo-HSCT) for neuroblastoma and other solid tumors do not rely on escalation of chemotherapy intensity and tumor load reduction but rather on a graft-vs-tumor effect. At this point, this is still an investigational and unusual application of allogeneic transplant, with 78 neuroblastoma patients reported to the European Group for Blood and Marrow Transplantation activity survey from 2002 to 2007 and less than 100 published cases. Two trends can be observed in the reviewed data: some teams have used allo-HSCT in children with refractory or progressive disease and significant tumor burden and other teams in children with CR, PR or minimal residual disease earlier in their disease process. Early studies of allo-HSCT in children with high-risk neuroblastoma suggest that this is a feasible approach that may improve outcome in this deadly disease. However, the proper timing for allo-HSCT during the disease course remains to be determined.
用于神经母细胞瘤和其他实体瘤的异基因造血干细胞移植（allo-HSCT）的新概念并不依赖于化疗强度的提升和肿瘤负荷的降低，而是依赖于移植物抗肿瘤效应。目前，这仍然是异基因移植的一种研究性且不常见的应用，2002年至2007年向欧洲血液和骨髓移植组活动调查机构报告的神经母细胞瘤患者有78例，发表的病例不到100例。在回顾的数据中可以观察到两种趋势：一些团队在患有难治性或进展性疾病且肿瘤负荷较大的儿童中使用allo-HSCT，而其他团队则在疾病进程较早阶段的完全缓解（CR）、部分缓解（PR）或微小残留病的儿童中使用。对高危神经母细胞瘤儿童进行allo-HSCT的早期研究表明，这是一种可行的方法，可能会改善这种致命疾病的治疗结果。然而，疾病过程中allo-HSCT的合适时机仍有待确定。
